These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19258274)

  • 1. Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children.
    Rakhmanina N; van den Anker J; Baghdassarian A; Soldin S; Williams K; Neely MN
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2532-8. PubMed ID: 19258274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
    Masquelier B; Breilh D; Neau D; Lawson-Ayayi S; Lavignolle V; Ragnaud JM; Dupon M; Morlat P; Dabis F; Fleury H;
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2926-32. PubMed ID: 12183249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and dosing regimen optimisation of lopinavir in Chinese adults infected with HIV.
    Niu WJ; Sun T; Liu L; Liu XQ; Zhang RF; Yin L; Wang JR; Jia XF; Lu HZ; Zhong MK; Jiao Z; Zhang LJ
    Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):456-465. PubMed ID: 30346663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.
    Robbins BL; Capparelli EV; Chadwick EG; Yogev R; Serchuck L; Worrell C; Smith ME; Alvero C; Fenton T; Heckman B; Pelton SI; Aldrovandi G; Borkowsky W; Rodman J; Havens PL;
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3276-83. PubMed ID: 18625762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.
    Verweel G; Burger DM; Sheehan NL; Bergshoeff AS; Warris A; van der Knaap LC; Driessen G; de Groot R; Hartwig NG
    Antivir Ther; 2007; 12(4):453-8. PubMed ID: 17668553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir.
    Delaugerre C; Teglas JP; Treluyer JM; Vaz P; Jullien V; Veber F; Rouzioux C; Chaix ML; Blanche S
    J Acquir Immune Defic Syndr; 2004 Oct; 37(2):1269-75. PubMed ID: 15385734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
    J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.
    Micheli V; Regazzi M; Dickinson L; Meraviglia P; Villani P; Khoo SH; Viganò P; Cordier L; Cusato M; Duca P; Orlando G; Rizzardini G; Back DJ; Cargnel A
    Ther Drug Monit; 2008 Jun; 30(3):306-13. PubMed ID: 18520602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents.
    Klinklom A; Puthanakit T; Gorowara M; Phasomsap C; Kerr S; Sriheara C; Ananworanich J; Burger D; Ruxrungtham K; Pancharoen C
    Antivir Ther; 2012; 17(2):283-9. PubMed ID: 22293065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.
    van Heeswijk RP; Bourbeau M; Seguin I; Giguere P; Garber GE; Cameron DW
    Br J Clin Pharmacol; 2005 Apr; 59(4):398-404. PubMed ID: 15801934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy.
    Chadwick EG; Pinto J; Yogev R; Alvero CG; Hughes MD; Palumbo P; Robbins B; Hazra R; Serchuck L; Heckman BE; Purdue L; Browning R; Luzuriaga K; Rodman J; Capparelli E;
    Pediatr Infect Dis J; 2009 Mar; 28(3):215-9. PubMed ID: 19209098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.
    Moltó J; Barbanoj MJ; Miranda C; Blanco A; Santos JR; Negredo E; Costa J; Domingo P; Clotet B; Valle M
    Clin Pharmacokinet; 2008; 47(10):681-92. PubMed ID: 18783298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results.
    Chadwick EG; Capparelli EV; Yogev R; Pinto JA; Robbins B; Rodman JH; Chen J; Palumbo P; Serchuck L; Smith E; Hughes M;
    AIDS; 2008 Jan; 22(2):249-55. PubMed ID: 18097227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection.
    Alexander CS; Montaner JS; Asselin JJ; Ting L; McNabb K; Harris M; Guillemi S; Harrigan PR
    Ther Drug Monit; 2004 Oct; 26(5):516-23. PubMed ID: 15385834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
    Bongiovanni M; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Bini T; Monforte Ad
    Int J Antimicrob Agents; 2005 Jul; 26(1):88-91. PubMed ID: 15878262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir/ritonavir (ABT-378/r).
    Qazi NA; Morlese JF; Pozniak AL
    Expert Opin Pharmacother; 2002 Mar; 3(3):315-27. PubMed ID: 11866671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children.
    Resino S; Bellón JM; Ramos JT; Navarro ML; Martín-Fontelos P; Cabrero E; Muñoz-Fernández MA
    Pediatr Infect Dis J; 2004 Oct; 23(10):923-30. PubMed ID: 15602192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
    Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
    Colombo S; Buclin T; Franc C; Guignard N; Khonkarly M; Tarr PE; Rochat B; Biollaz J; Telenti A; Decosterd LA; Cavassini M
    Antivir Ther; 2006; 11(1):53-62. PubMed ID: 16518960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood.
    Yang J; Nikanjam M; Best BM; Pinto J; Chadwick EG; Daar ES; Havens PL; Rakhmanina N; Capparelli EV
    J Clin Pharmacol; 2018 Dec; 58(12):1604-1617. PubMed ID: 30252146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.